Redmile Group, LLC
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 14, 2025), Redmile Group, LLC reported 40 stock positions worth $1.0 billion. Its top holding was Scholar Rock (SRRK) at 14.1% of the portfolio, followed by Krystal Biotech (KRYS, 11.4%) and Stoke Therapeutics (STOK, 9.5%). Compared with Q2 2025, it sold out of 8, added to 4 and reduced 21. The biggest buy was Cogent Biosciences (COGT, shares +53%) and the biggest sale Replimune (REPL, shares −89%).
- Most Recent 13F
- Q2 2026
- Location
- LARKSPUR, CA
- CIK
- 0001425738
- Portfolio Value
- $1.0B (Q3 2025)
- SEC Filing
- 0001104659-25-112572 ↗ filed Nov 14, 2025
Holdings Value
Holdings 40 stocks · $1.0B
| SRRK Scholar Rock Holding Corp. | 14.15% | 3,904,456 | $145.4M | Reduce -0.6% |
| KRYS Krystal Biotech Inc. | 11.36% | 661,388 | $116.8M | Reduce -0.3% |
| STOK Stoke Therapeutics Inc. | 9.55% | 4,175,542 | $98.1M | Reduce -4.6% |
| ZYME Zymeworks Inc. | 6.16% | 3,705,750 | $63.3M | Reduce -10.7% |
| ADCT Adc Therapeutics SA | 6.10% | 15,666,731 | $62.7M | No change |
| IMNM Immunome Inc. | 5.72% | 5,023,385 | $58.8M | Add +3.1% |
| LIVN Livanova PLC | 4.72% | 926,799 | $48.5M | Reduce -0.8% |
| RGNX Regenxbio Inc. | 4.41% | 4,693,389 | $45.3M | Reduce -1.7% |
| AKRO Akero Therapeutics Inc. | 3.45% | 747,818 | $35.5M | Reduce -3.4% |
| NRIX Nurix Therapeutics Inc. | 3.31% | 3,678,394 | $34.0M | Reduce -1.5% |
| BEAM Beam Therapeutics Inc. | 3.28% | 1,387,559 | $33.7M | Reduce -2.5% |
| COGT Cogent Biosciences Inc. | 3.09% | 2,209,118 | $31.7M | Add +52.6% |
| ABSI Absci Corp. | 2.44% | 8,253,316 | $25.1M | No change |
| NGNE Neurogene Inc. | 2.19% | 1,299,022 | $22.5M | Add +1.8% |
| ETNB 89BIO Inc. | 2.11% | 1,473,136 | $21.7M | Reduce -4.7% |
| IDYA Ideaya Biosciences Inc. | 1.96% | 742,017 | $20.2M | Add +71.6% |
| ANNX Annexon Inc. | 1.87% | 6,300,644 | $19.2M | No change |
| FATE Fate Therapeutics Inc. | 1.58% | 12,872,946 | $16.2M | No change |
| RAPT Rapt Therapeutics Inc. | 1.39% | 552,594 | $14.3M | Reduce -12.4% |
| STTK Shattuck Labs Inc. | 1.29% | 5,539,724 | $13.2M | No change |
| SLDB Solid Biosciences Inc. | 1.14% | 1,899,342 | $11.7M | Reduce -0.9% |
| SLN Silence Therapeutics PLC-ADR | 1.09% | 2,164,777 | $11.2M | No change |
| NUVB Nuvation Bio Inc. | 1.09% | 3,031,009 | $11.2M | No change |
| KROS Keros Therapeutics Inc. | 0.85% | 552,506 | $8.7M | No change |
| CLDX Celldex Therapeutics Inc. | 0.82% | 327,008 | $8.5M | Reduce -4.7% |
| ATRA Atara Biotherapeutics Inc. | 0.62% | 441,701 | $6.3M | No change |
| FOLD Amicus Therapeutics Inc. | 0.60% | 777,178 | $6.1M | Reduce -34.6% |
| ALXO Alx Oncology Holdings Inc. | 0.59% | 3,332,983 | $6.1M | Reduce -1.7% |
| ESTA Establishment Labs Holdings | 0.52% | 129,364 | $5.3M | Reduce -5.2% |
| CBLL Ceribell Inc. | 0.49% | 435,239 | $5.0M | No change |
| XERS Xeris Biopharma Holdings Inc. | 0.36% | 451,099 | $3.7M | No change |
| VTYX Ventyx Biosciences Inc. | 0.32% | 1,073,386 | $3.3M | Reduce -3.7% |
| LVTX Lava Therapeutics NV | 0.31% | 2,074,372 | $3.2M | No change |
| RPTX Repare Therapeutics Inc. | 0.27% | 1,586,174 | $2.8M | No change |
| IVVD Invivyd Inc. | 0.24% | 2,285,320 | $2.5M | No change |
| PLRX Pliant Therapeutics Inc. | 0.23% | 1,591,695 | $2.4M | Reduce -2.5% |
| REPL Replimune Group Inc. | 0.22% | 535,818 | $2.2M | Reduce -88.5% |
| PRME Prime Medicine Inc. | 0.05% | 87,118 | $483K | Reduce -95.8% |
| KLRS Kalaris Therapeutics Inc. | 0.05% | 82,955 | $479K | No change |
| BOLD Boundless Bio Inc. | 0.03% | 245,458 | $302K | Reduce -58.3% |
Portfolio Sells Q2 2025 → Q3 2025
| REPL Replimune Group Inc. | Reduce -88.5% | 0.22% | −4.39 |
| KYMR Kymera Therapeutics Inc. | Sold out | 0.00% | −3.73 |
| HNGE Hinge Health Inc. Class A | Sold out | 0.00% | −1.65 |
| NRIX Nurix Therapeutics Inc. | Reduce -1.5% | 3.31% | −1.22 |
| BHVN Biohaven Ltd. | Sold out | 0.00% | −1.10 |
| BSX Boston Scientific Corp. | Sold out | 0.00% | −0.98 |
| AKRO Akero Therapeutics Inc. | Reduce -3.4% | 3.45% | −0.94 |
| VERV Verve Therapeutics Inc. | Sold out | 0.00% | −0.88 |
| SRRK Scholar Rock Holding Corp. | Reduce -0.6% | 14.15% | −0.67 |
| PEN Penumbra Inc. | Sold out | 0.00% | −0.51 |
| PRME Prime Medicine Inc. | Reduce -95.8% | 0.05% | −0.50 |
| IGMS Igm Biosciences Inc. | Sold out | 0.00% | −0.35 |
| FOLD Amicus Therapeutics Inc. | Reduce -34.6% | 0.60% | −0.13 |
| ESTA Establishment Labs Holdings | Reduce -5.2% | 0.52% | −0.10 |
| FDMT 4D Molecular Therapeutics Inc. | Sold out | 0.00% | −0.04 |
| BOLD Boundless Bio Inc. | Reduce -58.3% | 0.03% | −0.03 |
| PLRX Pliant Therapeutics Inc. | Reduce -2.5% | 0.23% | +0.03 |
| VTYX Ventyx Biosciences Inc. | Reduce -3.7% | 0.32% | +0.07 |
| CLDX Celldex Therapeutics Inc. | Reduce -4.7% | 0.82% | +0.08 |
| SLDB Solid Biosciences Inc. | Reduce -0.9% | 1.14% | +0.15 |
| RGNX Regenxbio Inc. | Reduce -1.7% | 4.41% | +0.23 |
| LIVN Livanova PLC | Reduce -0.8% | 4.72% | +0.25 |
| ALXO Alx Oncology Holdings Inc. | Reduce -1.7% | 0.59% | +0.44 |
| ETNB 89BIO Inc. | Reduce -4.7% | 2.11% | +0.49 |
| ZYME Zymeworks Inc. | Reduce -10.7% | 6.16% | +0.61 |
| BEAM Beam Therapeutics Inc. | Reduce -2.5% | 3.28% | +0.70 |
| RAPT Rapt Therapeutics Inc. | Reduce -12.4% | 1.39% | +0.85 |
| KRYS Krystal Biotech Inc. | Reduce -0.3% | 11.36% | +1.65 |
| STOK Stoke Therapeutics Inc. | Reduce -4.6% | 9.55% | +4.26 |
Portfolio Buys Q2 2025 → Q3 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 39 | $1.5B | SRRK, KRYS, STOK, IMNM, NRIX |
| Q1 2026 | 35 | $1.5B | SRRK, KRYS, STOK, IMNM, NRIX |
| Q4 2025 | 34 | $1.4B | SRRK, KRYS, NRIX, STOK, IMNM |
| Q3 2025 | 40 | $1.0B | SRRK, KRYS, STOK, ZYME, ADCT |
| Q2 2025 | 48 | $939.6M | SRRK, KRYS, ZYME, STOK, IMNM |
| Q1 2025 | 56 | $1.1B | SRRK, KRYS, FOLD, ZYME, NRIX |
| Q4 2024 | 62 | $1.4B | SRRK, KRYS, NRIX, ZYME, FOLD |
| Q3 2024 | 63 | $1.7B | KRYS, NRIX, FOLD, IMNM, KYMR |
| Q2 2024 | 63 | $1.7B | KRYS, FOLD, NRIX, STOK, IMNM |
| Q1 2024 | 77 | $2.7B | KRYS, FOLD, IMNM, SRRK, FATE |